Slide 1: Developing a Novel Approach to Treat Metastatic Solid Tumors
Developing a Novel Approach to Treat Metastatic Solid Tumors James Nathanielsz, Chief Executive Officer j.nathanielsz@propanc.com | www.propanc.com
Slide 2: Forward-Looking Statement
Forward-Looking Statement The information in this presentation is provided to you by Propanc Biopharma, Inc. (the “Company”) solely for informational purposes and is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any security or instrument of the Company, or to participat
Slide 3: Senior Leadership with Extensive Experience
Senior Leadership with Extensive Experience Management James Nathanielsz Dr. Julian Kenyon Prof. Klaus Kutz Mr. Josef Zelinger Chief Executive & Chief Chief Scientific Officer Chief Medical Officer Non-Executive Director Financial Officer Co-Founder & Director, Feb 25 yrs. Experience in Clinical
Slide 4: Offering New Hope to Cancer Patients
Offering New Hope to Cancer Patients Generated compassionate use (CU) data across 46 terminal patients where 41% exceeded life expectancy without any serious adverse events Initially targeting Pancreatic and Ovarian cancers with combined TAM of $14.3B and long-term strategy of targeting metastatic s
Slide 5: Large Addressable Market with Unmet Need
Large Addressable Market with Unmet Need Global Cancer Treatment Market Size $251.18B ~$111B 91% Global metastatic cancer of cancer cases are solid market by 2027 tumors CAGR 9.2% ~$14.3B 1.8M Global Pancreatic and Ovarian New cases of $164B cancer markets by 2027 solid tumors in the U.S. ~$4.2B ~$1
Slide 6: Focused Pipeline Candidates
Focused Pipeline Candidates Indications Drug Candidate Discovery Preclinical Phase 1 Phase 2 Status PRP Pancreatic Cancer (ODD*) Initiate Phase Ib in 2H 2026; Interim (Trypsinogen + results expected in Ovarian Cancer Chemotrypsinogen) 2026 POP1 Entering preclinical Synthetic development 2H (Trypsino
Slide 7: PRP
PRP A synergistic combination of Trypsinogen and Chymotrypsinogen
Slide 8: Technology Based on Pancreatic Enzyme Therapy
Technology Based on Pancreatic Enzyme Therapy Propanc Biopharma's PRP (Proenzyme Therapy) offers a groundbreaking approach to treating metastatic solid tumors, addressing critical challenges in the cancer treatment market. Selective Targeting of Tumor Cell Targeting Cancer Stem Cells Proenzyme Thera
Slide 9: Proenzyme Formulation Derived from Pancreas
Proenzyme Formulation Derived from Pancreas 12000.00 A2780 - Ovarian Mixture of 2 10000.00 proenzymes from 8000.00 bovine pancreas RFU +/- SEM 6000.00 4000.00 2000.00 0.00 Synergistic ratio of 1:6 Chymotrypsinogen Combination inhibits growth of most tumor cells, in vitro 10000.00 HCT-15 - Colorectal
Slide 10: Truly Novel Mechanism of Action
Truly Novel Mechanism of Action 1 Targets CSCs Inhibits Cancer Stem Cells (CSC) Related Genes 2 Prevents Metastasis Differentiates Malignant Cells to Become Safer 3 Blocks Messengers Primary Tumor Signal Interference www.propanc.com 10
Slide 11: Suppresses EMT Process and Metastasis
Suppresses EMT Process and Metastasis 1 Up-Regulation Promotes RAC1b; Preventing Hyper-activation of TGF- β Pathway 2 Multiple Pathways Regulates Four Pathways Relating to Cancer Spread & Metastasis of CSCs 3 Inhibits the EMT These events Inhibits inhibit the EMT the Process EMT Thatprocess Leads to
Slide 12: Alters EMT Signaling Pathways
Alters EMT Signaling Pathways Cancer stem cells die naturally by reprogramming the cancer stem cell to reduce malignancy and invasiveness PRP promotes the expression of E-cadherin and decreases expression of N-cadherin & vimentin mesenchymal markers Strongly inhibits Slug, a transcription factor ass
Slide 13: Compassionate Use (CU) Study Data
Compassionate Use (CU) Study Data Mean survival of 9 46 terminal patients No severe, or even More than 40% of months; significantly administered serious adverse patients significantly higher than mean life suppository events observed from exceeded life expectancy (5.6 Mo.), formulation treatment exp
Slide 14: Improving on Compassionate Use Results
Improving on Compassionate Use Results 1 2 3 4 Formulation Administration Systemic Exposure Dosing Regime Optimized Improved Dosing will be Compassionate PRP will be an IV Because of weekly vs daily use study was administration, synergistic ratio allowing for a meant as a proof making it a far and d
Slide 15: CU Data Highlights Market Value
CU Data Highlights Market Value Compassionate use study highlighted 41% of patients exceeded life expectancy with the average survival of patients almost doubling from 5.6 months at original prognosis to 9 months. Additionally, there was a superior safety profile with no serious adverse events obser
Slide 16: PRP Phase 1b Study Design
PRP Phase 1b Study Design Design Objectives Timing • Open-label, multicenter, non- • Primary: Determine maximum tolerated • From first dose to trial completion, the comparative, safety and dose (MTD) of PRP in patients with study will be a 6-month review period and pharmacokinetic study of PRP advan
Slide 17: POP1 / Rec-PRP
POP1 / Rec-PRP Human Recombinant Version of PRP
Slide 18: Rec-PRP Program: Synthetic Enzymes
Rec-PRP Program: Synthetic Enzymes Our research has produced synthetic versions of the two proenzymes using a novel expression system to achieve high titers of recombinant trypsinogen and chymotrypsinogen Anti-cancer effects to be tested against naturally derived proenzymes of bovine origin Goal to
Slide 19: Rec-PRP Demonstrated Preclinical Results
Rec-PRP Demonstrated Preclinical Results Novel therapeutic formulation based on Demonstrated the the combination of reduced viability of human recombinant CSCs and decreased trypsinogen & the expression of CSC chymotrypsinogen markers produced synthetically Showed a similar anti- tumor effect when S
Slide 20: Corporate Overview
Corporate Overview
Slide 21: Therapeutic Landscape
Therapeutic Landscape Targeted Therapies Monoclonal PRP Therapy Chemotherapeutics (e.g., Multi-targeted Immunotherapy Antibodies kinase inhibitors) Pain, diarrhoea, constipation, mouth sores, Skin and gastrointestinal Skin and gastrointestinal No severe or serious side Fatigue, rash, hand-foot Sever
Slide 22: Standard of Care vs PRP
Standard of Care vs PRP PRP Pancreatic Cancer Ovarian Cancer Standard of Care Responders 3/4 5/7 Pancreatic Cancer Ovarian Cancer No severe, or even serious side effects observed 5 Year Survival Rate < 12% ~29% Preclinical Evidence: Surgery, • Evidence against pancreatic CSC induced tumors with impo
Slide 23: Early Data Shows Promise Among Alternatives
Early Data Shows Promise Among Alternatives Ticker ELEV FGEN TNGX Share Price $4.41 $1.71 $11.13 Market Cap. $187M $169M $1.1B Phase of Dev. Ph.1 Study Ongoing Ph.3 Ongoing Ph. 1/2 Ongoing Overview MOA is fully human antibody Uncertainty around PRMT5 class / Claudin 18.2 targeting ADC; comes against
Slide 24: Clinical Development Timelines
Clinical Development Timelines Months 1 2 3 4 5 6 7 8 9 10 11 12 Investigational Medicinal Product Dossier (IMPD) Study Protocol (SP) Investigator‘s Brochure (IB) CTA-Review CTA Compilation CTA-Submission CTA Approval Study Preparation CRO Selection & Contracts Analytical Labs Selection Contracts Pr
Slide 25: Expansive & Novel IP Portfolio
Expansive & Novel IP Portfolio Portfolio consists of 90 patents covering Another 2 – 3 patent applications in important discoveries regarding preparation covering composition of proenzymes and their anti-cancer effects matter & method of use A pharmaceutical composition for Proenzyme composition Can
Slide 26: Regulatory Strategy
Regulatory Strategy Scientific advice ODD status received Further national advice If Ph 2 results clinically meetings with MHRA: from US FDA for to be obtained for Ph 2 meaningful, direct treatment of pancreatic in EU, most likely at pathway towards All non-clinical data to cancer Paul-Ehrlich-Insti
Slide 27: Funding Snapshot
Funding Snapshot Use of Funds Seeking $4 – 6M: 4% 14% 12% Finished product manufacture & completion of Phase I, FIH study, for PRP Initiating preclinical testing of Rec-PRP from POP1 drug discovery program Phase I & II clinical studies in AUS to receive 43% R&D tax incentive, incl. OS expenses
Slide 28: What’s Next?
What’s Next? Significant Value Already Short Timelines and Limited Capital Unlocked Required for Next Milestones Completed Tasks Planned Activities Preparation for Ph.1B, FIH Study in advanced cancer Scientific advice meetings with MHRA (UK) patients Preclinical pharmacology and safety toxicology st
Slide 29: Investment Highlights
Investment Highlights Generated compassionate use (CU) data across 46 terminal patients where 41% exceeded life expectancy without any serious adverse events Initially targeting Pancreatic and Ovarian cancers with combined TAM of $14.3B and long-term strategy of targeting metastatic solid tumors (~$